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Abstract
Postoperative delirium (POD) and postoperative (neuro- )cognitive disorder (POCD) 
are frequent and serious complications after operations. We aim to investigate the 
association between pre- operative polypharmacy and potentially inappropriate medi-
cations and the development of POD/POCD in elderly patients. This investigation 
is part of the European BioCog project (www.biocog.eu), a prospective multicenter 
observational study with elderly surgical patients. Patients with a Mini- Mental State 
Examination score less than or equal to 23 points were excluded. POD was assessed 
up to 7 days after surgery using the Nursing Delirium Screening Scale, Confusion 
Assessment Method (for the intensive care unit [ICU]), and a patient chart review. 
POCD was assessed 3  months after surgery with a neuropsychological test bat-
tery. Pre- operative long- term medication was evaluated in terms of polypharmacy 
(≥5 agents) and potentially inappropriate medication (defined by the PRISCUS and 
European list of potentially inappropriate medications [EU(7)- PIM] lists), and asso-
ciations with POD and POCD were analyzed using logistic regression analysis. Eight 
hundred thirty- seven participants were included for analysis of POD and 562 partici-
pants for POCD. Of these, 165 patients (19.7%) fulfilled the criteria of POD and 60 
(10.7%) for POCD. After adjusting for confounders, pre- operative polypharmacy and 
intake of potentially inappropriate medications could not be shown to be associated 
with the development of POD nor POCD. We found no associations between pre- 
operative polypharmacy and potentially inappropriate medications and development 
of POD and POCD. Future studies should focus on the evaluation of drug interactions 
to determine whether patients benefit from a pre- operative adjustment.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Polypharmacy and drugs listed on PRISCUS or European list of potentially inappro-
priate medications (EU(7)- PIM) lists are associated with higher hospitalization rates, 
increased morbidity, and poorer outcome regarding quality of life. Studies examining 
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INTRODUCTION
Postoperative delirium (POD) is an acute and sudden 
change in the mental state, characterized by fluctuating lev-
els of attention, consciousness, and cognition.1 The occur-
rence of POD is associated with increased complication and 
mortality rates,2,3 and may be related to the development 
of mild and major postoperative (neuro- )cognitive disorder 
(POCD).4– 6
Incidence depends on predisposing and precipitating 
risk factors.7,8 Age- related changes in brain metabolism, 
such as neurodegeneration, neurotransmitter imbalances, 
microcirculation disorders, altered penetration of the 
blood- brain- barrier, and modulations in intracellular sig-
nal transduction, increase the vulnerability of the brain 
to stress factors.9 Therefore, older people are particularly 
susceptible to POD.
At the same time— due to the accumulation of comorbid-
ities— an increasing amount of medication is prescribed to 
elderly patients. Polypharmacy and potentially inadequate 
medication may have an additional influence on cognition. 
Although there is no uniform definition for polypharmacy, it 
is generally described in literature as the long- term intake of 
greater than or equal to 5 prescription- free and/or prescrip-
tion drugs.10,11 To address the increased risk of adverse drug 
reactions, especially for older people, the German PRISCUS 
list was published in 2010,12 which served as basis for the 
2015 European list of potentially inappropriate medications 
(EU(7)- PIM).13 Drugs from the PRISCUS and EU(7)- PIM 
lists should be avoided whenever possible in elder patients. It 
has been shown that patients with polypharmacy and drugs 
listed on the PRISCUS or EU(7)- PIM lists have a higher 
hospitalization rate due to adverse drug events, have poorer 
outcome in terms of quality of life, and an increased morbid-
ity after hospitalization.14
Awareness and modulation of predisposing and precip-
itating risk factors15 in pre- operative, intra- operative, and 
postoperative settings are crucial for the prevention of POD 
and POCD. Prevention strategies can reduce the in- hospital 
incidence of delirium by 30%– 40%.16 Although former 
studies in the field of peri- operative medicine focused on 
the relationship of POD and polypharmacy, there is still a 
lack of studies using a structured assessment of long- term 
medication in terms of potentially inadequate medication, 
according to the PRISCUS and EU(7)- PIM lists, in ad-
dition to polypharmacy, on the development of POD and 
POCD. If the application of the lists or the screening for 
polypharmacy can reliably identify patients at risk for the 
development of POD and POCD, severe implications can 
be prevented or reduced through the early initiation of pri-
mary prevention strategies.
In this study, we aim to investigate the association 
between pre- operative polypharmacy and potentially in-
appropriate medications (defined by the PRISCUS and 
EU(7)- PIM lists) and the development of POD and POCD 
in elderly patients.
METHODS
Study design and population
This investigation was performed as part of the BioCog project 
(www.biocog.eu), a prospective multicenter observational 
study conducted at the Charité – Universitätsmedizin Berlin, 
Department of Anesthesiology and Operative Intensive Care 
Email: claudia.spies@charite.de
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such medication in addition to polypharmacy and the occurrence of postoperative 
delirium/postoperative (neuro- )cognitive disorder (POD/POCD) are lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
Is there an association between preoperative polypharmacy and potentially inappro-
priate medications (defined by PRISCUS and EU(7)- PIM lists) and the development 
of POD and POCD in elderly patients?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Pre- operative polypharmacy and intake of potentially inappropriate medications were 
not associated with the development of POD or POCD. It may be reasonable to focus 
on the evaluation of drug interactions rather than sole avoidance of listed medications.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
Based on these results, simply considering the number of drugs or screening for po-
tentially inadequate medication is insufficient as a preventive strategy regarding POD 
and POCD. Future studies should consider drug interactions and use randomized 
controlled approaches to determine the interaction of predisposing and precipitating 
factors.
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Medicine, Berlin, Germany, and the University Medical 
Center Utrecht, Department of Intensive Care Medicine, 
Utrecht, The Netherlands. The BioCog study aims to estab-
lish biomarker panels for risk and clinical outcome predic-
tion of POD and POCD.17 The study was approved by the 
local Ethics Committees (ref.: EA2/092/14 and 14– 469), and 
conducted in accordance with the Declaration of Helsinki 
(ClinicalTrials.gov: NCT02265263). Written informed con-
sent was obtained from each patient, and all local data pri-
vacy regulations were followed.
We included patients aged greater than or equal to 65 years 
of European descent, who underwent elective surgery with an 
expected surgical duration greater than or equal to 60 min, 
provided they were able to provide informed consent, and 
could undergo magnetic resonance imaging. We excluded pa-
tients with a Mini- Mental State Examination score less than 
or equal to 23 points, homeless patients, and others who could 
not be reached by telephone or postal services for follow- up 
examinations. In addition, we excluded patients enrolled in 
other prospective interventional studies, those who were ac-
commodated in an institution due to an official or judicial 
order, and patients with conditions limiting the conduction 
of neurocognitive testing, such as neuropsychiatric disease, 
anacusis/hypoacusis, and language barriers.
Baseline measurements
The following baseline measurements were collected to 
describe the study population: age, sex, physical status ac-
cording to the American Society of Anesthesiologists 
Physical Status (ASA PS), Charlson Comorbidity Index 
(CCI),18 pre- existing neurocognitive disorder (NCD; for 
details see Supplementary Material), frailty status (for de-
tails see Supplementary Material), duration of anesthesia, 
site of surgery (intrathoracic/- abdominal/- pelvic, periph-
eral, and intracranial operations), and education according 
to the International Standard Classification of Education 
(ISCED).19 In addition, Geriatric Depression Scale20 was re-
corded 3 months after surgery.
Postoperative delirium
POD was defined according to the 5th edition of Diagnostic 
and Statistical Manual of Mental Disorders (DSM- 5) crite-
ria.1 Patients were considered delirious in case of:
• greater than or equal to 2 cumulative points on the Nursing 
Delirium Screening Scale (Nu- DESC) and/or
• a positive Confusion Assessment Method (CAM) score 
and/or
• a positive CAM for the ICU (CAM- ICU) and/or
• patient chart review that showed descriptions of delirium 
(e.g., confused, agitated, drowsy, disorientated, delirious, 
and received antipsychotic therapy).
Delirium screening was started in the recovery room 
and repeated twice per day at 08:00 and 19:00 (±1 h) up to 
7 days after surgery. Delirium assessment was conducted in-
dependently of the routine hospital procedures by a research 
team, which was trained and supervised by psychiatrists and 
delirium experts.
Postoperative cognitive dysfunction
To identify POCD, a neuropsychological test battery consist-
ing of noncomputerized and computerized tests was performed 
before surgery, at discharge from the hospital or on the seventh 
postoperative day, and 3 months after surgery. The composi-
tion and retest reliabilities of the test battery are described in 
an additional publication.21 Trained doctoral students and study 
nurses performed the testing based on a standard operating pro-
cedure, which was approved by two neuropsychologists.
POCD was defined using an R algorithm described 
in another publication22 that applied the Reliable Change 
Index (RCI) with the International Analysis of Postoperative 
Cognitive Dysfunction (ISPOCD) criteria proposed by 
Rasmussen.23 Missing values that were attributable to techni-
cal difficulties or external disturbances were imputed at ran-
dom using the missForest package in R software environment 
(R Core Team 2017; R: A language and environment for sta-
tistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL https://www.R- proje ct.org/). Missing 
information due to disturbed attention or confusion of the pa-
tients (e.g., inability to understand standardized test instruc-
tions) for some but not all tests were imputed with the value 
of the worst performance.
Long- term medication
The pre- operative long- term medication was assessed dur-
ing the pre- operative anesthesia consultation by means of 
anamnesis, patient’s medical record, or medication prescrip-
tions. Long- term medication included both prescription and 
prescription- free drugs, which were taken regularly at the 
time of the consultation. Long- term medication was evalu-
ated with regard to polypharmacy and potentially inappropri-
ate medication. Polypharmacy was defined as greater than or 
equal to 5 agents10,11 and potentially inappropriate medica-
tion was defined according to the PRISCUS12 and EU(7)- 
PIM13 lists. An initial analysis merely regarded the presence 
of polypharmacy and the intake of (any) potentially inap-
propriate medication. This was followed by an analysis to 
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consider the number of regularly taken medication and the 
number of potentially inadequate agents.
For a descriptive analysis, the pre- operative long- term 
medication was additionally divided into groups according 
to the Anatomic Therapeutic Chemical (ATC) classification 
system.24
Statistical analysis
Baseline characteristics were expressed as median and 
lower and upper quartile, or frequencies with percentages. 
Differences between the groups were tested using Mann- 
Whitney U test or χ2 test.
The associations between pre- operative polypharmacy 
and potentially inappropriate medications (defined by the 
PRISCUS and EU(7)- PIM lists) and the development of POD 
and POCD were investigated using multivariable logistic re-
gression analysis, adjusting for possible confounding vari-
ables. Confounders were chosen a priori and included age, 
CCI, frailty status, pre- existing NCD, duration of anesthesia 
and site of surgery for the regression analysis of POD, and 
age, ASA PS, frailty status, depression 3 months after sur-
gery (defined as >4 points in GDS), and education (accord-
ing to ISCED, with regard to levels 1– 4, which corresponds 
to a lower educational level) for the regression analysis of 
POCD. A separate regression analysis was performed for 
each investigated variable (polypharmacy, potentially inap-
propriate medication, number of agents, and the number of 
potentially inadequate agents according to the PRISCUS and 
EU(7)- PIM lists). No adjustments were made for multiple 
testing.
All analyses were performed with IBM SPSS Statistics, 
version 23 (Copyright 1989, 2015 by SPSS Inc., Chicago, IL) 
and in R software environment.
RESULTS
From October 2014 to April 2017, 1033 participants were 
enrolled at 2 study centers (Berlin, Germany and Utrecht, 
The Netherlands). Accounting for early dropouts, missing 
data, and loss to follow- up, 837 participants could be in-
cluded for analysis of POD and 562 participants for analy-
sis of POCD (see Figure 1). Of these, 165 patients (19.7%) 
fulfilled the criteria of POD and 60 (10.7%) for POCD (see 
Tables 1 and 2). Patients with POD were significantly older, 
had higher ASA PS and CCI scores, and longer duration 
of anesthesia. In addition, there were group differences re-
garding to frailty status and site of surgery. Patients with 
POCD were older, had higher ASA PS scores, and were 
found to fulfill frailty criteria more often than patients with-
out POCD. Patients with POCD did not differ in sex, CCI, 
duration of anesthesia, and site of surgery compared with 
patients without POCD.
Operations were most frequently performed on the mus-
culoskeletal system (27.8%) and digestive tract (18.5%; see 
Table  S1 for additional information). Surgical procedures 
F I G U R E  1  Flow Chart. POCD, 
postoperative delirium; POD, postoperative 
(neuro- )cognitive disorder
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were categorized into three types prior to analysis, whereas 
43.4% of all operations were intrathoracic, - abdominal, or 
pelvic, 55.5% were peripheral, and 1.1% were intracranial.
Information on long- term medication was available for 838 
patients. Only 87 patients did not take any medication, and 
the remaining 751 patients with long- term medication took 







Age [years] 74 [70; 77] 71 [68; 75] <0.001a 
Sex
Female 79 (47.9%) 283 (42.1%) 0.180b 
ASA PS
1– 2 77 (46.7%) 463 (68.9%) <0.001b 
3– 4 88 (53.3%) 209 (31.1%)
CCI 1.86 ± 1.5 1.31 ± 1.5 <0.001a 
Pre- existing NCD
No NCD 102 (69.4%) 462 (76.7%) 0.176b 
Mild NCD 25 (17.0%) 80 (13.3%)
Major NCD 20 (13.6%) 60 (10.0%)
Frailty status
Robust 37 (22.7%) 256 (38.6%) <0.001b 
Pre- frail 87 (53.4%) 337 (50.8%)






168 [105– 255] <0.001a 
Site of surgery




105 (63.6%) 248 (36.9%)
Peripheral 58 (35.2%) 416 (61.9%)
Polypharmacy 88 (53.3%) 285 (42.4%) 0.011b 
Medication 
(PRISCUS list)




98 (59.4%) 319 (47.5%) 0.006b 
Number of agents 5.41 ± 3.7 4.44 ± 3.8 0.002a 
Number of agents 
according to 
PRISCUS list
0.16 ± 0.4 0.13 ± 0.4 0.503a 
Number of agents 
according to 
EU(7)- PIM list
0.96 ± 1.0 0.78 ± 1.0 0.008a 
Note: Data are expressed as median [25th quartile; 75th quartile], or as 
mean ± SD except for categorical data, which are expressed as frequencies 
(percentages). Any p ≤ 0.05 was considered as statistically significant.
Abbreviations: ASA PS, physical status according to the American Society of 
Anesthesiologists; CCI, Charlson Comorbidity Index; EU(7)- PIM, European list 
of potentially inappropriate medications; NCD, neurocognitive disorder; POD, 
postoperative delirium.
aThe p values refer to the Mann– Whitney U test between patients with or 
without POD.
bThe p values refer to the χ2 test between patients with or without POD.







Age [years] 74 [70; 79] 72 [68; 75] 0.001a 
Sex
Female 28 (46.7%) 197 (39.2%) 0.267b 
ASA PS
1– 2 32 (53.3%) 361 (71.9%) 0.003b 
3– 4 28 (46.7%) 141 (28.1%)
CCI 1.52 ± 1.6 1.19 ± 1.4 0.075a 
Frailty status
Robust 20 (33.3%) 204 (41.0%) 0.008b 
Pre- frail 27 (45.0%) 249 (50.1%)
Frail 13 (21.7%) 44 (8.9%)
Duration of anesthesia 
[min]
179 [100; 294] 188 [117; 277] 0.476a 
Site of surgery




23 (38.3%) 204 (40.6%)
Peripheral 35 (58.3%) 295 (58.8%)
Polypharmacy 32 (53.3%) 206 (41.0%) 0.068b 
Medication (PRISCUS 
list)
9 (15.0%) 66 (13.1%) 0.690b 
Medication (EU(7)- 
PIM list)
30 (50.0%) 235 (46.8%) 0.640b 
Number of agents 5.50 ± 4.0 4.32 ± 3.3 0.032a 
Number of agents 
according to the 
PRISCUS list
0.15 ± 0.4 0.14 ± 0.4 0.719a 
Number of agents 
according to the 
EU(7)- PIM list
0.95 ± 1.2 0.75 ± 1.0 0.285a 
Note: Data are expressed as median [25th quartile; 75th quartile], or as 
mean ± SD except for categorical data, which are expressed as frequencies 
(percentages). Any p ≤ 0.05 was considered as statistically significant.
Abbreviations: ASA PS, physical status according to the American Society of 
Anesthesiologists; CCI, Charlson Comorbidity Index; EU(7)- PIM, European 
list of potentially inappropriate medications; POCD, postoperative cognitive 
dysfunction.
aThe p values refer to the Mann– Whitney U test between patients with or 
without POCD.
bThe p values refer to the χ2 test between patients with or without POCD.
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a median of 4 agents (3851 agents in total; see Table S2).24 
Usually, no adjustment of medication was made at admis-
sion. Pantoprazole was the most frequently taken medication 
(5%), followed by metoprolol (4.2%), simvastatin (4.0%), 
hydrochlorothiazide (3.2%), levothyroxine (3.2%), and ace-
tylsalicylic acid (2.9%). As shown in Figures 2 and 3, the dis-
tribution of the frequencies of the agents did not differ with 
respect to POD and POCD.
Overall, 45% of all patients (n = 838) fulfilled the crite-
ria for polypharmacy, 11.9% took potentially inappropriate 
medication according to the PRISCUS list, and 49.8% ac-
cording to EU(7)- PIM list. The most common inappropriate 
drug taken according to the PRISCUS list were amitripty-
line (18.2%), doxazosin (12.7%), and temazepam (8.2%). 
According to the EU(7)- PIM list, pantoprazole (28.3%), 
omeprazole (7.6%), and spironolactone (3.8%) were the most 
commonly consumed drugs.
When analyzing group differences, patients with POD 
were more often affected by polypharmacy and more often 
took potentially inappropriate medication according to the 
EU(7)- PIM list (see Table  1). Furthermore, patients with 
POD took more agents in general, as well as more agents 
according to the EU(7)- PIM list. There were no group dif-
ferences with regard to the PRISCUS list. In the multivari-
able logistic regression analysis, none of the investigated 
variables (polypharmacy, potentially inappropriate med-
ication according to the PRISCUS and EU(7)- PIM lists, 
number of agents, and number of agents according to the 
PRISCUS and EU(7)- PIM lists) associated with POD 
reached a level of significance (see Table 3). However, in 
each regression model, age, duration of anesthesia, positive 
frailty criteria, and intrathoracic/- abdominal/- pelvic opera-
tions (vs. peripheral operations) were significantly associ-
ated with POD.
When analyzing group differences, patients with POCD 
took more agents in general. No other group differences be-
tween POCD and non- POCD could be identified regarding 
polypharmacy or potentially inappropriate medication (see 
Table  2). Similarly, in the multivariable logistic regression 
analysis, none of the investigated variables displayed an 
association with POCD (see Table 4). However, in each re-
gression model, age and ASA PS were significantly and con-
sistently associated with POCD.
DISCUSSION
This study aimed to investigate the association between pre- 
operative polypharmacy and the intake of potentially inappro-
priate medications (defined by the PRISCUS and EU(7)- PIM 
F I G U R E  2  Illustration of frequencies of the groups of substances 
of the pre- operative long- term medication in regard to POD. Groups 
of substances according to Anatomical Therapeutic Chemical 
classification system.24 For an overview of the groups, see Table S2. 
Presentation as bar plots: grey = POD and black = no POD. The 














F I G U R E  3  Illustration of frequencies of the groups of substances 
of the preoperative long- term medication in regard to POCD. Groups 
of substances according to Anatomical Therapeutic Chemical 
classification system.24 For an overview of the groups, see Table S2. 
Presentation as bar plots: grey = POCD and black = no POCD. The 
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lists) and the development of POD and POCD in elderly pa-
tients. This investigation included patients undergoing elec-
tive surgery across a wide range of surgical disciplines.
After adjustment for confounding factors, pre- operative 
polypharmacy and the intake of potentially inappropriate 
medications could not be shown to be associated with the 
development of POD or POCD. Incidences within our study 
sample were comparable with other cohorts, with nearly 
20% of patients developing POD and nearly 10% develop-
ing POCD.25– 28 Overall, 45% of all patients were affected 
by polypharmacy. This is in line with other studies investi-
gating elderly patients in peri- operative context.10,11 In our 
cohort, 12% took potentially inappropriate medication ac-
cording to the PRISCUS list. The German PRISCUS list 
was created with a selective literature search, an analysis of 
international PIM lists, and a Delphi survey in two rounds 
(a comprehensive, structured expert survey), and includes 
83 drugs.12 When the PRISCUS list was introduced in 2010, 
retrospective studies in elderly patients reported preva-
lences of 22%– 25%,29– 31 whereas more recent studies show 
a prevalence of 10%– 14%.32,33 This indicates that after the 
introduction of the PRISCUS list, prescriptions practices 
have changed to avoid inadequate drugs. According to the 
EU(7)- PIM list, however, 50% of the patients in our cohort 
took potentially inappropriate medication. The EU(7)- PIM 
list was based on the PRISCUS list and other international 
PIM lists. Experts from seven countries have extended the 
list, suggesting further medications, which was followed by 
a Delphi survey in two rounds. The list contains 282 drugs.13 
The number of drugs included in each list help explain the 
observed difference between the prevalences according to 
the PRISCUS and EU(7)- PIM lists, and that in the simple 
group comparison patients with POD took drugs from the 
EU(7)- PIM list more frequently. Furthermore, prevalence 
of inadequate medication according to the EU(7)- PIM list 
varies considerably in literature, with values fluctuating be-
tween 37% and 81%.33– 37 Similarly to the above described 
trend, a declining prevalence could be observed in studies 
conducted after the introduction of the EU(7)- PIM list in 
2015. Large national differences in the prescription of agents 
listed on the (internationally available) EU(7)- PIM list have 
been reported. For example, the prescription prevalence of 
drugs listed on the EU(7)- PIM list was 41% in a Swedish 
cohort,36 60% in a Brazilian cohort,34 and 80% in a Belgian 
cohort.37 Differences might be explained in part by the age 
of the respective cohorts (≥80 years in the Belgian study). 
Furthermore, differences in prescriptions are related to re-
gional differences in guidelines and the availability of drugs. 
In contrast to the German PRISCUS list, the internationally 
known EU(7)- PIM list must consider location as a factor 
when comparing studies. Pantoprazole, omeprazole, and spi-
ronolactone were the most commonly consumed drugs ac-
cording to the EU(7)- PIM list in our cohort, compared with 
apixaban and zopiclone in a Swedish cohort,38 benzodiaz-
epines, proton pump inhibitors, and tramadol in a Croatian 
cohort,39 and proton pump inhibitors, benzodiazepines, 
and glibenclamide in a Brazilian cohort.34 In addition, the 





Polypharmacy 1.076 [0.707; 1.639] 0.732
Medication (PRISCUS list) 0.924 [0.511; 1.670] 0.794
Medication (EU(7)- PIM list) 1.217 [0.791; 1.873] 0.371
Number of agents 1.025 [0.964; 1.089] 0.431
Number of agents according to 
the PRISCUS list
1.017 [0.619; 1.672] 0.947
Number of agents according to 
the EU(7)- PIM list
0.949 [0.792; 1.137] 0.569
Note: Entered variables into analysis: age (years), CCI, frailty status, pre- 
existing neurocognitive disorder, duration of anesthesia, and site of surgery. 
Data are expressed as OR and 95% CI. Any p ≤ 0.05 was considered as 
statistically significant. A separate regression analysis was performed for each 
investigated variable (polypharmacy, medication [PRISCUS list], medication 
[EU(7)- PIM list], number of agents, number of agents according to PRISCUS or 
EU(7)- PIM list).
Abbreviations: CI, confidence interval; CCI, Charlson Comorbidity Index; 
EU(7)- PIM, European list of potentially inappropriate medications; OR, odds 
ratio; POD, postoperative delirium.





Polypharmacy 0.971 [0.497; 1.896] 0.931
Medication (PRISCUS list) 1.139 [0.497; 2.608] 0.759
Medication (EU(7)- PIM list) 0.564 [0.288; 1.105] 0.095
Number of agents 1.018 [0.928; 1.117] 0.702
Number of agents according to 
PRISCUS list
0.969 [0.466; 2.015] 0.933
Number of agents according to 
EU(7)- PIM list
0.932 [0.706; 1.229] 0.616
Note: Entered variables into analysis: age (years), ASA PS, frailty status, 
depression 3 months after surgery (defined as >4 points in GDS) and education 
(according to ISCED, with regard to level 1– 4 which corresponds to a lower 
educational level). Data are expressed as OR and 95% CI. Any p ≤ 0.05 was 
considered as statistically significant.
A separate regression analysis was performed for each investigated variable 
(polypharmacy, medication [PRISCUS list], medication [EU(7)- PIM list], 
number of agents, number of agents according to PRISCUS or EU(7)- PIM list.
Abbreviations: ASA PS, physical status according to the American Society 
of Anesthesiologists; CI, confidence interval; EU(7)- PIM, European list of 
potentially inappropriate medications; GDS, Geriatric Depression Scale; ISCED, 
International Standard Classification of Education; OR, odds ratio; POCD, 
postoperative (neuro- )cognitive dysfunction.
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application of the national PRISCUS list shows differences 
within Germany. Although in our cohort amitriptyline, dox-
azosin, and temazepam were the most commonly consumed 
drugs, according to the PRISCUS list, zopiclone and loraze-
pam,40 or zopiclone, zolpidem, and amitriptyline41 were re-
ported as most common agents in two other German cohorts. 
In our view, the differences can be explained not only by re-
gional conditions but also by the age and setting of the co-
horts. Our study is, to the best of our knowledge, the only one 
which analyze a peri- operative cohort. On the other hand, the 
most frequently used substance classes in general, as well as 
the frequency of use, are comparable to other European co-
horts.42,43 Interestingly, older patients in American cohorts, 
for example, tend to take significantly more medication than 
their European counterparts.44,45
So far, there is no evidence that the drugs most frequently 
taken in our cohort (pantoprazole, metoprolol, simvastatin, 
hydrochlorothiazide, levothyroxine, acetylsalicylic acid, 
omeprazole, spironolactone, or doxazosin) could be associ-
ated with the development of POD or POCD. According to 
current hypotheses, only amitriptyline and temazepam would 
promote delirium through their anticholinergic effects.46 So, 
currently, there are no investigations on temazepam. For 
amitriptyline, no association could be confirmed in another 
study.47
In our analysis, special attention should be given to the fact 
that the incidences of POD and POCD depend on predispos-
ing and precipitating risk factors that are often inter- related. 
According to the evidence- based and consensus- based 
guideline on postoperative delirium of the European Society 
of Anaesthesiology,7 advanced age and comorbidities are 
predisposing factors, whereas duration and site of surgery 
are precipitating risk factors for POD. Advanced age and 
comorbidities are also risk factors for POCD, in addition to 
alcohol abuse, low education level, or perioperative compli-
cations.25,48 This is also reflected in our results. In addition, 
we could not find any group differences between patients with 
POCD and without POCD regarding duration of anesthesia 
or site of surgery. In this context, it should be noted that there 
are also indications in the literature that POD and POCD co- 
occur and share risk factors, but their relationship remains 
unclear.4 In addition, a biphasic pattern was described in the 
relationship between POD and POCD.6 Here, we observed 
that the cognitive performance of patients with POD recov-
ers 3 months after surgery, but shows severe deterioration in 
the long term. This could help explain why an association of 
EU(7)- PIM with POD was observed, but not with POCD in 
the descriptive, unadjusted analyses.
Furthermore, pre- existing NCD, reduced functional 
status, and malnutrition are also considered predisposing 
risk factors for elderly surgical patients. This could ex-
plain why group differences could be observed in descrip-
tive, unadjusted analysis, but not in the logistic regression 
analysis. Comorbidities are more frequently observed in el-
derly patients, and medication is often the primary method 
of treatment. Polypharmacy or medication according to the 
EU(7)- PIM list may therefore be an expression of these risk 
factors and help explain the group differences.
Another plausible approach is that patients with pre- 
existing NCD or frailty are particularly vulnerable to the 
side effects of drugs and their related toxicity, thus increas-
ing the risk of developing POD or POCD. In the context 
of polypharmacy, this toxicity- vulnerability interaction 
might be amplified by drug- drug interactions,49 the like-
lihood of potentially inappropriate medication, and the in-
crease of medication discrepancies (mismatch between the 
medication actually taken by the patient and the medica-
tion recorded in the patient’s medical record or medication 
prescriptions).50
Furthermore, although current recommendations call for 
checking the presence of polypharmacy and to critically re-
view prescription indications (also with regard to potentially 
inappropriate medication), no general recommendations ex-
ists to reduce polypharmacy or the intake of potentially in-
appropriate medication once identified.51– 53 The “Primary 
Medical Care” (Primärmedizinische Versorgung [PMV]) 
Research Group recommends the PRISCUS list “as an aid 
for critically evaluating medications and not as a list of for-
bidden drugs.”54 This recommendation is not yet based on 
appropriate evidence, but underlines the importance of an 
individualized treatment of each patient.
Our analysis could not confirm that screening for poly-
pharmacy or the application of the PRISCUS or EU(7)- PIM 
list can reliably identify patients at risk for development 
of POD or POCD prior to surgery. Future analyses should 
therefore adopt other approaches, considering time- 
dependent effects, dose levels of inappropriate drugs, as 
well as the impact of bridging of inappropriate or benefi-
cial drugs before surgery, in addition to drug interactions. 
Furthermore, the association of drugs that are not on these 
lists, but which are known to cause alterations of the phys-
iological processes, should also be investigated in regard 
to the development of POD and POCD. These approaches 
could be applied to verify whether patients benefit from a 
pre- operative adjustment of long- term medication aimed at 
reducing possible harmful and toxic drug reactions in pa-
tients with high vulnerability.
Strength and limitations
A key strength of this study is the prospective multicenter 
design. In addition, POD and POCD were characterized by a 
comprehensive, standardized, complex, and validated assess-
ment. For POCD, the neuropsychological test battery covered 
various cognitive domains, and was carried out following a 
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well- described standard with limited rater effects. A compre-
hensible algorithm in R is available to improve comparison 
of our results with other studies. The study database also 
contains extensive information on possible confounders. In 
addition, we were able to investigate the associations over a 
wide range of surgical disciplines, which reflects the condi-
tions that apply to the pre- operative risk evaluation settings 
in clinical practice.
Nevertheless, some important limitations must be con-
sidered. In our cohort, the incidence of POCD is relatively 
low with ~ 10%, which limits the statistical power. The wide 
range of surgical disciplines increased the study population’s 
variance in characteristics.
CONCLUSIONS
In conclusion, when considering confounders, there were no 
associations between pre- operative polypharmacy and the 
intake of potentially inappropriate medications and the de-
velopment of POD and POCD. However, further studies are 
needed to determine whether and how patients benefit from a 
pre- operative adjustment of long- term medication.
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